Abstract
Acute myocardial infarction (AMI) is a frequent and disabling disease, which is the first cause of cardiovascular mortality worldwide. Infarct size is a major determinant of myocardial functional recovery and mortality after AMI. Limitation of infarct size thus appears as an appropriate strategy to prevent post-ischemic heart failure and improve survival. Reperfusion is the only treatment recommended to reduce infarct size but despite obvious benefits, it may also have deleterious effects called ischemia-reperfusion (IR) injury including myocyte cell death.
Proteins involved in the apoptosis cascade generally interact over large surfaces lacking well-defined pockets. Therefore, inhibitory peptides are optimal biomolecules to target these large protein surfaces, they are often more selective to their target than conventional small organic molecules, and they can be tailored for optimal affinity or desired metabolic property. Since peptides do not cross freely biological membranes, they are generally administered in association with cell penetrating peptides (CPPs) and with homing peptides (HPs) for selective organs or tissues targeting. As a first approach in vivo, we made use of the already known BH4 peptidic inhibitor of the mitochondrial apoptotic pathway, which showed cardioprotective properties in a murine model of AMI after a single bolus of intravenous administration.
More importantly, similar peptidic strategies and tools are likely to be adaptable to many other situations in which cells have to be protected from apoptosis such as stroke or organ transplantation.
Keywords: Anti-apoptotic peptide, ischemia-reperfusion, cell penetrating peptides, cardioprotection, systemic delivery, in vivo
Current Pharmaceutical Design
Title:CPP-conjugated Anti-apoptotic Peptides as Therapeutic Tools of Ischemiareperfusion Injuries
Volume: 19 Issue: 16
Author(s): Prisca Boisguerin, Jean-Michel Giorgi and Stephanie Barrere-Lemaire
Affiliation:
Keywords: Anti-apoptotic peptide, ischemia-reperfusion, cell penetrating peptides, cardioprotection, systemic delivery, in vivo
Abstract: Acute myocardial infarction (AMI) is a frequent and disabling disease, which is the first cause of cardiovascular mortality worldwide. Infarct size is a major determinant of myocardial functional recovery and mortality after AMI. Limitation of infarct size thus appears as an appropriate strategy to prevent post-ischemic heart failure and improve survival. Reperfusion is the only treatment recommended to reduce infarct size but despite obvious benefits, it may also have deleterious effects called ischemia-reperfusion (IR) injury including myocyte cell death.
Proteins involved in the apoptosis cascade generally interact over large surfaces lacking well-defined pockets. Therefore, inhibitory peptides are optimal biomolecules to target these large protein surfaces, they are often more selective to their target than conventional small organic molecules, and they can be tailored for optimal affinity or desired metabolic property. Since peptides do not cross freely biological membranes, they are generally administered in association with cell penetrating peptides (CPPs) and with homing peptides (HPs) for selective organs or tissues targeting. As a first approach in vivo, we made use of the already known BH4 peptidic inhibitor of the mitochondrial apoptotic pathway, which showed cardioprotective properties in a murine model of AMI after a single bolus of intravenous administration.
More importantly, similar peptidic strategies and tools are likely to be adaptable to many other situations in which cells have to be protected from apoptosis such as stroke or organ transplantation.
Export Options
About this article
Cite this article as:
Boisguerin Prisca, Giorgi Jean-Michel and Barrere-Lemaire Stephanie, CPP-conjugated Anti-apoptotic Peptides as Therapeutic Tools of Ischemiareperfusion Injuries, Current Pharmaceutical Design 2013; 19 (16) . https://dx.doi.org/10.2174/1381612811319160011
DOI https://dx.doi.org/10.2174/1381612811319160011 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The ATP-driven Hsp60 Machinery: Biological and Clinical Implications
Current Immunology Reviews (Discontinued) Implications for Endothelium-Derived Hyperpolarizing Factor (EDHF) in Womens Cardiovascular Health
Current Women`s Health Reviews miR-25 Mediates Retinal Degeneration Via Inhibiting ITGAV and PEDF in Rat
Current Molecular Medicine Sodium-glucose Co-transporters 2 Inhibitors: The Miraculous Route from Hypoglycemic to Cardiovascular Drugs
Cardiovascular & Hematological Disorders-Drug Targets Current Genomics in Cardiovascular Medicine
Current Genomics Methionine-Derived Metabolites in Apoptosis: Therapeutic Opportunities for Inhibitors of their Metabolism in Chemoresistant Cancer Cells
Current Medicinal Chemistry Characteristics of Brain Tumor Stem Cells and the Rationale for Applying Tyrosine Kinase Inhibitors as Potential Targeting Agents
Recent Patents on Regenerative Medicine The Role of Flavonoids in Inhibiting IL-6 and Inflammatory Arthritis
Current Topics in Medicinal Chemistry Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry Arterial Mechanics and Dynamics in Hypertension
Current Hypertension Reviews Aurora B: A New Prognostic Marker and Therapeutic Target in Cancer
Current Medicinal Chemistry The Anti-Cancer Charm of Flavonoids: A Cup-of-Tea Will Do!
Recent Patents on Anti-Cancer Drug Discovery Treatment of Psoriasis: A Comprehensive Review of Entire Therapies
Current Drug Safety Toll-Like Receptors and Myocardial Ischemia/Reperfusion, Inflammation, and Injury
Current Cardiology Reviews Dyslipidemia, Metabolic Syndrome and Vascular Disease Among Asian Indians
Vascular Disease Prevention (Discontinued) Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity
Current Medicinal Chemistry Endothelial Dysfunction in Heart Failure: Mechanisms and Therapeutic Approaches
Current Vascular Pharmacology Current Understanding of the Mechanism and Role of ROS in Angiotensin II Signal Transduction
Current Pharmaceutical Biotechnology Transdermal Therapeutic System of Enalapril Maleate Using Piperidine as Penetration Enhancer
Current Drug Delivery The Mechanistic Links Between Proteasome Activity, Aging and Agerelated Diseases
Current Genomics